CYP2D15, while M2 (N-desmethyltramadol) is formed by multiple
CYPs including CYP2B11, CYP3A12, CYP2C21, and CYP2C41. This mirrors human drug metabolism well in that M1 is solely formed by CYP2D6, while M2 is formed by CYP2B6 and CYP3A4. We also showed that dog liver microsomes (DLMs), when compared to cat and human liver microsomes, do not produce high amounts of the M1 metabolite relative to the M2 metabolite. This may explain in part relatively low circulating concentrations of M1 in dogs (Giorgi, Del Carlo, Saccomanni, Lebkowska-Wieruszewska, & Kowalski, 2009; Itami et al., 2013; Kogel et al., 2014; Kukanich & Papich, 2011) compared with humans (Ardakani & Rouini, 2007; Garcia Quetglas, Azanza, Cardenas, Sadaba, & Campanero, 2007; Grond, Meuser, Uragg, Stahlberg, & Lehmann, 1999; Scott & Perry, 2000) and cats (Cagnardi et al., 2011; Pypendop & Ilkiw, 2008; Pypendop, Siao, & Ilkiw, 2009 ) after administration of tramadol to each species. This is clinically relevant because M1, and not M2 or the parent compound, is thought to have analgesic properties mediated by μ-opioid agonist activity at therapeutic doses (Gillen, Haurand, Kobelt, & Wnendt, 2000; Raffa et al., 1992) .
Further oxidative metabolism of M1 and M2 is also possible through N-demethylation (of M1) or O-demethylation (of M2) to form the M5 metabolite (N,O-didesmethyltramadol). After tramadol administration to dogs, M5 was found in plasma at concentrations that were approximately similar to M2 and tramadol concentrations but higher (by about 20-fold) than M1 concentrations (Giorgi, Del Carlo et al., 2009; Kukanich & Papich, 2011) . However, M5 has much weaker μ-opioid agonist efficacy and potency (by about 30 times) when compared to M1 by in vitro testing (Gillen et al., 2000) . Furthermore, a recent study in rats indicates that M5 has lower penetration into the central nervous system (CNS) in that CSF to plasma concentration ratios after tramadol administration were less than 0.1 for M5, while M1, M2, and tramadol showed ratios of 0.3, 0.4, and 0.44, respectively (Sheikholeslami, Gholami, Lavasani, & Rouini, 2016) . This low ratio for M5 (3-fold less than M1) may be a consequence of higher polarity and lower membrane solubility, or active efflux from the CNS by a membrane transporter such as p-glycoprotein. Given the poor brain permeability and the low potency and efficacy of M5, the formation of M5 from M1 may contribute to reduction in the μ-opioid antinociceptive effects of M1. However, the identity of CYP enzymes forming M5 from M1 or from M2 has not been reported (for any species).
In this study, we initially evaluated species differences in the formation rates of (+)-M5 from (+)-M1 and from (+)-M2 by DLMs, compared with cat and human liver microsomes. We studied the (+)-enantiomers of the metabolites here since, although tramadol is used clinically as a racemic mixture, there is evidence that (+)-M1 is a more potent μ-opioid agonist than (-)-M1 (Gillen et al., 2000) , and we have previously observed somewhat faster formation rates of (+)-M1 from tramadol compared with (−)-M1 formation (Perez Jimenez et al., 2016) . We then used different approaches (canine recombinant enzymes, chemical inhibition, and hepatic microsomes from inducer-treated dog) to identify the CYPs involved in the formation of (+)-M5 from (+)-M1 and from (+)-M2 in dog liver. Given the structural similarities between (+)-tramadol compared with (+)-M1 and (+)-M2 as substrates (i.e., they only differ by a methyl group that is away from the demethylation site), we hypothesized that Odemethylation of (+)-M2 would be performed mainly by CYP2D15, while N-demethylation of (+)-M1 would be performed by multiple CYPs including CYP2B, CYP2C, and CYP3A isoforms. Finally, we used a competitive transport assay to evaluate whether (+)-tramadol, (+)-M1, (+)-M2, or (+)-M5 are substrates of canine P-glycoprotein, which could limit CNS distribution via the blood-brain barrier.
| MATERIAL S AND ME THODS

| Reagents
and racemic N,O-didesmethyltramadol-d3 (#D294702) were ac- The bicinchoninic acid assay was used (Thermo Scientific Pierce, Rockford, IL) to measure the protein content of the dog, human, and cat liver microsomes used in this study.
| Assay to measure (+)-M5 formation rates from (+)-M1 and from (+)-M2
Assays were developed to measure the rate of formation of (+)- 
| Inhibition assays
Sulfaphenazole (100 μmol/L), chloramphenicol (10 μmol/L), and quinidine (10 μmol/L) were evaluated as inhibitors of (+) For all inhibition assays, samples were prepared in duplicate, (+)-M5 formation rates were averaged and then expressed as a percentage of control incubations that lacked inhibitor.
| Canine P-glycoprotein substrate assessment
A cell-based competitive efflux assay was used to determine whether tramadol, M1, M2, or M5 are substrates for canine P-glycoprotein as previously described (Mealey, Dassanayake, & Burke, 2017) . Briefly, 
| Enzyme kinetic and statistical analyses
Kinetic and statistical analyses were performed using Sigmaplot 12 software (Systat, San Jose, CA). For enzyme kinetic analysis, enzyme kinetics parameters (Km and Vmax) were determined using the one enzyme Michaelis-Menten model using nonlinear regression analysis. The model of best fit was evaluated based upon plots of fitted vs. observed data. Enzyme kinetic analyses were performed using pooled DLMs (n = 59 of various breeds and sexes) and DLMs from three different dogs chosen at random from our liver bank (Dog 10-female Greyhound; Dog 31-male Beagle; Dog 46-male Beagle).
| RE SULTS
| Species differences in (+)-M5 formation rates from (+)-M1 and (+)-M2
The formation rates of (+)-M5 from (+)-M1 at 10 μmol/L concentration ( Figure 1a) and from (+)-M2 at 0.5 μmol/L concentration ( Figure 1b) were then compared using pooled liver microsomes from dogs (n = 59), humans (n = 48), and cats (n = 16). These substrate concentrations were chosen to approximate Km values for these activities based on preliminary studies using pooled DLMs. Pooled DLMs demonstrated the highest activities (by 3-to 19-fold) for both reactions compared with cat and human liver microsomes. Human and cat liver microsomes both displayed low activities with (+)-M1 as substrate, while cat liver microsomes were intermediate between human and DLMs with (+)-M2 as substrate.
We then compared previously published results (Perez Jimenez et al., 2016) for formation rates of (±)-M1 and (±)-M2 from (±)-tramadol to the current results for the metabolism of (+)-M1 and (+)-M2 to (+)-M5 determined using the same pooled dog, human and cat liver microsomes. As F I G U R E 1 Species differences in the rates of (+)-M5 formation rates from (+)-M1 at 10 μmol/L concentration (panel a) and from (+)-M2 at 0.5 μmol/L concentration (panel b) by pooled dog (n = 59), human (n = 48), and cat (n = 16) liver microsomes. Bars represent the mean (± SD) of three independent determinations performed in triplicate. Also shown for each species are the ratios of the mean formation rate of (±)-M1 from (±)-tramadol (reported previously in Perez Jimenez et al., 2016) to the mean formation rate of (+)-M5 formation from (+)-M1 (panel c); as well as the ratios of the mean formation rate of (±)-M2 from (±)-tramadol (reported previously in Perez Jimenez et al., 2016) to the mean formation rate of (+)-M5 formation from (+)-M2 (panel d) F I G U R E 2 Michaelis-Menten enzyme kinetic plots of (+)-M5 formation rates from (+)-M1 (panel a) and (+)-M5 formation from (+)-M2 (panel c) by pooled (n = 59) dog liver microsomes. Also shown are Eadie-Hofstee plots of these same data (panels b and d, respectively). Each data point represents the mean of two independent determinations performed in duplicate, and the curves represent the model of best fit to the data shown in Figure 1c , feline liver microsomes showed an M1 formation-tometabolism ratio of 1926 that was much higher than ratios for DLMs (42) and human liver microsomes (71). On the other hand (Figure 1d ), feline liver microsomes showed an M2 formation to metabolism ratio of 1.7 that was slightly lower than ratios for DLMs (3.1) and human liver microsomes (2.9). substrates. These substrate concentrations were chosen because they approximated (or were below) the Km values for the reaction by DLMs to ensure that the enzymes were not saturated. As shown in Figure 3a , formation rate of (+)-M5 from (+)-M1 was highest for CYP2C21 with somewhat lower activities for CYP2C41 and CYP2B11, while only very low activities were detected for the other CYPs tested including CYP3A12, CYP2D15, CYP1A1, CYP1A2, and CYP3A26. On the other hand, the formation rate of (+)-M5 from (+)-M2 was only detected for CYP2D15 as seen in Figure 3b .
| Enzyme
| (+)-M5 formation rate from (+)-M1 and (+)-M2 by recombinant dog CYPs
As the abundance of different CYPs is known to differ within dog liver, these specific activities were also adjusted for reported typical abundance values (Heikkinen, Lignet, Cutler, & Parrott, 2015) for each CYP (except for CYP1A1 and CYP2C41 which were not available) and compared with pooled DLM activities measure at the same substrate concentration (Heikkinen et al., 2015) . As shown in Figure 3c , CYP2C21 was the predominant CYP mediating formation of (+)-M5 from (+)-M1 with similar activities to pooled DLMs. Liver abundance adjusted CYP2D15 activities were also similar to pooled DLMs for (+)-M5 formation from (+)-M2 (Figure 3d ).
| Effect of CYP selective inhibitors on (+)-M5 formation rate from (+)-M1 and (+)-M2
The effects of CYP selective inhibitors on (+)-M5 formation rate from (+)-M1 and (+)-M2 were evaluated using pooled DLMs and recombinant enzymes. Inhibitors included quinidine at 10 μmol/L as a CYP2D15 inhibitor (Roussel et al., 1998) , chloramphenicol at 10 μmol/L as a CYP2B11 inhibitor (Hay Kraus, Greenblatt, Venkatakrishnan, & Court, 2000) and sulfaphenazole at 100 μmol/L as a CYP2C inhibitor (Baldwin et al., 1995) . As shown in Figure 4a 
| Effect of CYP selective inducers on (+)-M5 formation rate from (+)-M1 and (+)-M2
The effects of selective inducers including β-naphthoflavone (CYP1A), phenobarbital (CYP2B and CYP2C), rifampin (CYP3A), and clofibric acid (CYP4A) on the formation of (+)-M5 from (+)-M1 and (+)-M2 were evaluated using pooled liver microsomes from male Beagle dogs (2 per treatment) that had been treated with each of these inducers. Results were compared to vehicle treated liver microsomes.
Vehicles included corn oil for rifampin and ß-naphthoflavone, and saline for phenobarbital and clofibric acid. As shown in Figure 5a , the formation of (+)-M5 from (+)-M1 was substantially increased by phenobarbital with mean ± SD activity that was 27 ± 0.1 times the control activity. Other inducers tested had less than 1.5-fold average difference compared with control for (+)-M5 formation from (+)-M1.
On the other hand, the formation of (+)-M5 from (+)-M2 (Figure 5b) was not substantially affected by any of the inducers tested, with TA B L E 1 Enzyme kinetic parameters determined by nonlinear regression for formation rate of (+)-M5 from (+)-M1 and (+)-M2 by liver microsomes pooled from 59 dogs (pDLMs) and liver microsomes prepared individually from three dogs (Dogs 10, 31, and 46). The data points used for fitting were the average of two independent experiments performed in duplicate (data points are shown in Figure 1 with less than 2.5-fold average difference from the activities of the respective vehicle controls.
| (+)-M1, (+)-M2, (+)-M5, and (+)-tramadol as canine P-glycoprotein substrates
The 
| D ISCUSS I ON
The results of this study substantially enhance our understanding of the complex pathways involved in tramadol metabolism in dogs generally considered to be unaffected by typical CYP inducers (Benedetti, 2000; Martignoni, Groothuis, & de Kanter, 2006; Parkinson, Mudra, Johnson, Dwyer, & Carroll, 2004; Pelkonen, Maenpaa, Taavitsainen, Rautio, & Raunio, 1998) .
Similar to the results of our previous study that showed involvement of both CYP2C21 and CYP2C41 in (±)-M2 formation rate from (±)-tramadol, we also showed that both enzymes could also metabolize (+)-M1 to (+)-M5. Overlap of substrate preference between CYP2C21 and CYP2C41 is not surprising given the high sequence similarity (70% amino acid identity) between these two enzymes (Blaisdell, Goldstein, & Bai, 1998) . CYP2C41 is of interest as it is affected by a gene deletion polymorphism (Blaisdell et al., 1998) . The prevalence of this gene among dogs does not appear to be high at Previous studies in rats indicated that M5 has lower brain permeability than tramadol or the other major metabolites (Sheikholeslami et al., 2016) . One possible cause of poor brain penetration is significant efflux by the P-glycoprotein transporter located at the bloodbrain barrier. Transwell experiments using human intestinal Caco-2 cell line monolayers previously demonstrated that both tramadol and M1 were not substrates of human P-glycoprotein (Kanaan, Daali, Dayer, & Desmeules, 2009 ). However, it is currently unknown whether M2 and M5 are P-glycoprotein substrates. In this study, we used a validated canine P-glycoprotein efflux competition assay (Mealey et al., 2017) and so the results should be of direct relevance to the pharmacokinetics of tramadol and metabolites in dogs. The results showed fluorescence intensity ratios for (+)-tramadol, (+)-M1, (+)-M2, and (+)-M5 that were indistinguishable from the negative control and much lower than the positive control indicating that these compounds are not substrates for canine P-glycoprotein.
Consequently, the poor brain penetration of M5 compared with tramadol and M1 may be a consequence of the higher polarity of this metabolite rather than efflux by P-glycoprotein from the CNS.
Alternatively, M5 might be a substrate for a different efflux transporter such as BCRP. There is also some evidence that tramadol and M1 may be substrates for brain uptake transporters (Kanaan et al., 2009; Kitamura, Higuchi, Okura, & Deguchi, 2014) , and so a lack of uptake transport of M5 might explain the observed differential blood-brain barrier permeability of these compounds.
Our results showed that (+)-M5 is formed from (+)-M1 and (+)-M2 more rapidly in dog livers compared with human and cat livers (Figure 1a,b) . This difference could contribute to the higher proportion of M5 and M5 conjugates as a percentage of total metabolites found in dog urine (43%) compared with human urine (12%-28%) (Lintz, Erlaçin, Frankus, & Uragg, 1981) . Although relatively high M1 plasma concentrations (similar to tramadol concentrations) have been reported after intravenous tramadol administration to cats (Cagnardi et al., 2011; Pypendop et al., 2009) , the presence or concentrations of other metabolites have not yet been reported.
Using our previously published data, we also compared the ratios of formation of M1 (and M2) from tramadol to the oxidation of M1
(and M2) to M5 (respectively) between species. Although M1 and to M5 was much higher for cat liver compared with human and dog liver microsomes (Figure 1c) . This difference may contribute to the relatively high circulating M1 concentrations reported in cats (Cagnardi et al., 2011; Pypendop et al., 2009) . It is also possible that higher M1
concentrations may result from slower conjugation of M1 in cats compared with other species, given the known propensity of cats to glucuronidate many drugs relatively slowly .
However, additional studies are needed to confirm this hypothesis.
A recent study failed to detect M5 in dog plasma after intravenous M1 administration (KuKanich, KuKanich, & Black, 2017), which might indicate that M1 conjugation is a more important clearance mechanism in dogs compared with M1 oxidation to M5.
While this may be true, M5 is also extensively conjugated in dogs (Giorgi, Del Carlo et al., 2009; Lintz et al., 1981) , and since plasma samples in that study were not deconjugated before analysis conjugated M5 would not have been detected.
Although this study was limited to liver and recombinant enzymes, some CYPs occur in substantial amounts in the small intestinal mucosa and can contribute to first pass metabolism after oral drug administration. A previous study (Heikkinen et al., 2015) showed that CYP3A12 and CYP2B11 proteins are highly expressed in canine intestinal mucosa, while CYP2C21 and CYP2D15 were not detected. Based on the results of our previous work (Perez Jimenez et al., 2016) and the current study, we would predict that dog intestinal mucosa could form M2 but not M1 from tramadol. However, there would not be further metabolism of M2 to M5, at least until M2 reaches the liver. Shown are metabolite formation rates measured using microsomes prepared from inducer treated male Beagle dogs (pooled from two dogs per treatment) expressed as a ratio of the formation rates measured in microsomes from the respective vehicle treated dogs (control activity). Vehicles were corn oil for rifampin and ß-naphthoflavone and saline for phenobarbital and clofibric acid. Bars represent the mean (± SD) of three independent determinations performed in triplicate F I G U R E 6 Primary and secondary CYP-dependent pathways of (+)-tramadol metabolism that have been phenotyped in dog liver. A previous study (Perez Jimenez et al., 2016) Oral co-administration of tramadol with CYP inhibitors could potentially increase bioavailability by reducing first-pass metabolism, and selectively decrease formation of certain metabolites. Kukanich et al. (2017) showed increased oral bioavailability of tramadol when co-administered with the CYP3A inhibitors ketoconazole and cimetidine. This is consistent with the known role of CYP3A12 in metabolism of tramadol to M2 (Perez Jimenez et al., 2016 ) and the high expression of CYP3A12 in intestinal mucosa and liver (Heikkinen et al., 2015) . They also observed slight increases in M1 and M2 concentrations in plasma, which probably resulted from the overall increase in tramadol systemic availability. Interestingly, although M5 concentrations were increased with cimetidine, M5 concentrations were substantially decreased with ketoconazole suggesting inhibition of M5 formation by CYP2D15.
This is supported by a previous study that showed relatively potent inhibition (IC50 = 0.47 μmol/L) of CYP2D15 mediated dextromethorphan o-demethylation in DLMs (Aidasani, Zaya, Malpas, & Locuson, 2008) .
The results of the present study predict that oral coadministration of tramadol with a CYP2B11 and CYP2C21 inhibitor would enhance systemic availability by reducing M2 formation from tramadol and increase plasma M1 concentrations by inhibiting M5
formation from M1. Conversely, induction of these enzymes such as by co-treatment with phenobarbital would reduce tramadol systemic availability and limit plasma M1 concentrations. However, it should be noted that M1 conjugation by sulfation and glucuronidation may be an important determinant of M1 concentrations in the dog and so future in vitro and in vivo work is needed to understand the impact of inhibitors, inducers, and genetic polymorphisms on these pathways.
A limitation of the present study is that we did not evaluate the metabolism of (-)-stereoisomers which would be generated with clinical use of racemic (±)-tramadol. In our previous study 
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